A platform to track
hair-loss treatment
outcomes over time.
Sunday evening, 9 PM. A 35-year-old marketing manager in her brightly lit bathroom pulls a small clump of hair from her brush and stares into the mirror — anxious, unable to tell if the topical solution she has used for three months is doing anything at all.A composite patient, three months in
Individuals on hair-loss treatments have no objective way to measure whether expensive regimens — topicals, procedures, prescriptions — are actually working.
A platform that tracks and visualizes hair-loss treatment outcomes over time, so progress is measured instead of guessed.
Competitive position scored 3/10 — Hairly, MyHair.ai and Hairscope.ai already offer AI photo-tracking.
Customer validation is high (8/10) — Reddit shows loud, frequent frustration with current tracking.
Margins are SaaS-grade (80% gross), but the 667-customer break-even hinges on a sub-$50 D2C CAC.
| Dimension | Score | Confidence | Key factor |
|---|---|---|---|
| Customer validation | 8/10 | High | Reddit (r/FemaleHairLoss, r/tressless) shows significant patient frustration and a clear, unmet need for better progress tracking. |
| Market opportunity | 8/10 | High | A large market ($50B+) with high willingness to pay — procedures cost up to $15,000. |
| Competitive position | 3/10 | High | Saturated with direct competitors (Hairly, Hairscope.ai, MyHair.ai). Claimed differentiation is non-existent. |
| Economic viability | 6/10 | Medium | High willingness to pay suggests customers may pay; a SaaS model is viable but hinges on a low CAC in a noisy D2C market. |
| Execution feasibility | 7/10 | High | Core AI image-analysis tech is proven and already used by competitors. The risk is distribution, not the build. |
The market splits into D2C tracking apps and B2B clinical software. The B2C side is crowded and undifferentiated — Hairly, MyHair.ai, Hairscope.ai and more all offer AI photo analysis, a sea of sameness with no clear leader. The biggest opening: a superior, trusted patient experience that can also bridge to clinicians.
| Competitor | Type | Overlaps | Rationale |
|---|---|---|---|
| Hairly ↗ | Direct | 👤🔥🧩🎯 |
Established D2C app; photo-based AI tracking already meets the core value prop. Out-focus, don't out-feature. |
| MyHair.ai ↗ | Direct | 👤🔥🧩🎯 |
AI analysis of user photos to monitor treatment effectiveness — the same promise, already shipping. |
| Hairscope.ai ↗ | Direct | 👤🔥🧩🎯 |
AI hair analysis that tracks health over time; leads with the technology. |
| HairMetrix ↗ | Indirect | 🔥🧩 |
In-clinic, physician-grade analysis — trusted but not a patient-facing, at-home tool. |
| Selfies + phone photo gallery | Substitute | 👤🔥🧩 |
Free and habitual, but subjective and inconsistent — no quantitative measure of change. |
Icons show where a rival overlaps with us — 👤 Customer · 🔥 Problem · 🧩 Solution · 🎯 Positioning
"Hairscope is an AI-powered platform for precise hair analysis and tracking hair health progression over time."
Doctors still track progression with manual, subjective methods — no dedicated platform.
Hair-restoration procedures (FUE) cost $4,000–$15,000 — a strong willingness-to-pay signal in the category.
Why some doctors are so ignorant. (rant)
Frequent complaints that doctors are ignorant and uncaring about hair loss — patients feel unheard.
Anyone else have completely useless doctors?
Frustration with the healthcare system and ‘useless doctors’ on hair loss and related issues.
How to help patients with hair loss feel seen / heard?
Clinicians discussing how to make hair-loss patients feel seen and heard — confirms real dissatisfaction.
Good window.
Low
Accessible AI, clear service gaps from both clinics and telehealth incumbents, and a consumer shift to data-driven health tracking create a strong window of opportunity.
High-quality phone cameras + commoditized AI image analysis make a consumer-grade quantitative tracker feasible for the first time.
Dermatologists track manually; telehealth giants (Hims, Ro) focus on prescriptions, not outcomes.
The ‘quantified self’ habit (Fitbit, Whoop) is expanding to specific conditions like hair loss.
HIPAA / FDA shifts could affect data handling or open markets — not an active driver today.
This platform can deliver a 10× better experience or more accurate tracking than the many existing competitors.
- Test
- Competitive analysis + interviews with users of competing products (Hairly, MyHair.ai).
- Pass if
- ≥50% of competitor users name a specific, significant flaw this solution can fix.
- Time / cost
- 48 hours, <$100 in incentives.
The go-to-market is D2C — users will proactively seek out and pay for a standalone tracking app.
- Test
- Interview dermatologists and clinic managers about interest in a B2B solution for their patients.
- Pass if
- 3 of 5 clinics show strong interest — if so, pivot the GTM toward B2B2C.
- Time / cost
- 1 week, minimal cost.
A D2C app can be marketed at a CAC low enough to be profitable on a ~$15/month subscription.
- Test
- Run experimental ad campaigns where the demographic is active (Instagram, TikTok, Reddit).
- Pass if
- Cost-per-install under $5 and cost-per-trial-signup under $20.
- Time / cost
- 2 weeks, $1,000 ad spend.
The pain is real, loud, and financially significant — but the category is saturated with no stated edge. Run the 48-hour test; if patients name the same unmet need and the reframe pulls, escalate to MAP to pick the wedge and ICP. The engine's best-wedge hint: a B2B2C play partnering with hair-restoration clinics to track post-op outcomes.
Biggest risk: a direct incumbent (Hairly, MyHair.ai) or a telehealth giant (Hims, Ro) adds richer outcome tracking before a wedge is established.
Escalate to MAP
A deep validation pass that sharpens the wedge this SCAN flagged. MAP adds:
- · ICP selection
- · Positioning wedge
- · Market sizing
- · Unit economics
- · Pivot options
- · 90-day plan